{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T22:59:12Z","timestamp":1649199552885},"reference-count":36,"publisher":"Walter de Gruyter GmbH","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n\t\t\t\t<jats:p><jats:bold>Background.<\/jats:bold> The aim of the study was evaluation of zoledronic acid with regard to safety, effect on analgesic consumption and impact on occurrence of skeletal related events in patients with bone lesions from solid tumors and multiple myeloma.<\/jats:p>\n\t\t\t\t<jats:p><jats:bold>Methods.<\/jats:bold> We conducted an observational, 12-month, phase IV and multi-center study. One hundred and twentyfive symptomatic (pain) bone-metastatic patients were included between 2007 and 2009: 92 prostate cancers, 28 multiple myelomas, 5 others. They were prescribed monthly infusions of zoledronic acid in accordance to each disease\u2019s treatment guidelines. Analgesics consumption, pain and laboratory values were evaluated.<\/jats:p>\n\t\t\t\t<jats:p><jats:bold>Results.<\/jats:bold> Zoledronic acid was prescribed concurrent to initial therapy for myeloma and only in late stage of prostate cancer. With treatment, percentage of patients on analgesics decreased in myeloma group (from 57% to 24%) and increased in prostate cancer group (from 70% to 88%). In patients with any analgesics, the use of opiates\u2019 prescription dropped from 72.9% to 64%, percentages of non-steroidal analgesics and other mild analgesics increased slightly. Pain score (Visual Analog Scale, VAS) decreased non significantly (by 22%) in prostate cancer but significantly in myeloma (by 97%). Hypocalcaemia grade 3 or 4 was observed in 4% of patients. Deviations in creatinine remained stable throughout. A total of 31 skeletal related events were reported for 10 patients (8%).<\/jats:p>\n\t\t\t\t<jats:p><jats:bold>Conclusions.<\/jats:bold> Zoledronic acid was safe medication. Different response of pain was seen between prostate cancer and myeloma patients, which might be due to different stages of disease where it was prescribed according to present guidelines. Possibility of earlier start of treatment should be explored in prostate cancer.<\/jats:p>","DOI":"10.2478\/raon-2013-0041","type":"journal-article","created":{"date-parts":[[2013,6,17]],"date-time":"2013-06-17T14:01:43Z","timestamp":1371477703000},"page":"289-295","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of safety and analgesic consumption in patients with advanced cancer treated with zoledronic acid"],"prefix":"10.2478","volume":"47","author":[{"given":"Andrej","family":"Kmetec","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tine","family":"Hajdinjak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","reference":[{"key":"ref351","first-page":"39","article-title":"ME in patients with cancer and skeletal metastases a systematic metaanalysis","volume":"15","author":"Peddi","year":"2013","journal-title":"review Cancer Treat Rev"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long - term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone - refractory prostate cancer","author":"Saad","year":"2004","journal-title":"Cancer Inst"},{"key":"ref341","article-title":"Common Terminology Criteria for Adverse Events data files Availabele th http ctep cancer gov protocolDevelopment electronic applications ctc htm ctc","volume":"14","author":"CTCAE","year":"2013"},{"key":"ref221","first-page":"23","article-title":"Malignant spinal compression","volume":"42","author":"Rajer","year":"2008","journal-title":"cord Radiol Oncol"},{"key":"ref291","first-page":"59","article-title":"EAU guidelines on prostate cancer Part II : Treatment of advanced relapsing and castration - resistant prostate cancer","author":"Mottet","year":"2011","journal-title":"Eur Urol"},{"key":"ref401","first-page":"141","article-title":"Complete clinical and biological response to zoledronic acid in castrate - resistant prostate cancer metastatic to bone","volume":"20","author":"Pouessel","year":"2012"},{"key":"ref21","first-page":"213","article-title":"Radiotherapy in palliative treatment of painful bone metastases","volume":"24","author":"Gojkovi\u010d Horvat","year":"2009","journal-title":"Radiol Oncol"},{"key":"ref391","article-title":"Openlabel trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone - sensitive prostate cancer and bone metastases","volume":"19","author":"Polascik","year":"2005","journal-title":"Urology"},{"key":"ref161","article-title":"Randomized double - blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer ( excluding breast and prostate cancer ) or multiple myeloma","volume":"17","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref241","first-page":"161","article-title":"mineral density in men treated with synthetic gonadotropin - releasing hormone agonists for prostatic carcinoma","volume":"22","author":"Maillefert","year":"1999","journal-title":"Bone"},{"key":"ref321","first-page":"003188","article-title":"Bisphosphonates in multiple myeloma a network meta - analysis CD","volume":"12","author":"Mhaskar","year":"2012","journal-title":"Database Syst Rev"},{"key":"ref151","first-page":"377","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration - resistant prostate cancer : a randomised double - blind study","volume":"16","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"ref231","first-page":"213","article-title":"Radiotherapy in palliative treatment of painful bone metastases","volume":"24","author":"Gojkovi\u010d Horvat","year":"2009","journal-title":"Radiol Oncol"},{"key":"ref101","first-page":"1","article-title":"CA Bisphosphonate therapy in multiple myeloma in preventing vertebral collapses : preliminary report","volume":"11","author":"Tamburrelli","year":"2012","journal-title":"Eur Spine J"},{"key":"ref251","first-page":"163","article-title":"Progressive osteoporosis during androgen deprivation therapy for prostate cancer","author":"Daniell","year":"2000"},{"key":"ref81","first-page":"59","article-title":"EAU guidelines on prostate cancer Part II : Treatment of advanced relapsing and castration - resistant prostate cancer","author":"Mottet","year":"2011","journal-title":"Eur Urol"},{"key":"ref141","first-page":"39","article-title":"ME in patients with cancer and skeletal metastases a systematic metaanalysis","volume":"15","author":"Peddi","year":"2013","journal-title":"review Cancer Treat Rev"},{"key":"ref311","first-page":"1","article-title":"CA Bisphosphonate therapy in multiple myeloma in preventing vertebral collapses : preliminary report","volume":"11","author":"Tamburrelli","year":"2012","journal-title":"Eur Spine J"},{"key":"ref411","first-page":"117","article-title":"Zoledronic acid use in cancer patients : more than just supportive care","volume":"21","author":"Coleman","year":"2011","journal-title":"Cancer"},{"key":"ref51","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/94.19.1458","article-title":"randomized placebo - controlled trial of zoledronic acid in patients with hormone - refractory metastatic prostate carcinoma","author":"Saad","year":"2002","journal-title":"Natl Cancer Inst"},{"key":"ref371","article-title":"Randomized double - blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer ( excluding breast and prostate cancer ) or multiple myeloma","volume":"17","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref31","first-page":"161","article-title":"mineral density in men treated with synthetic gonadotropin - releasing hormone agonists for prostatic carcinoma","volume":"22","author":"Maillefert","year":"1999","journal-title":"Bone"},{"key":"ref191","first-page":"141","article-title":"Complete clinical and biological response to zoledronic acid in castrate - resistant prostate cancer metastatic to bone","volume":"20","author":"Pouessel","year":"2012"},{"key":"ref361","first-page":"377","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration - resistant prostate cancer : a randomised double - blind study","volume":"16","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"ref131","article-title":"Common Terminology Criteria for Adverse Events data files Availabele th http ctep cancer gov protocolDevelopment electronic applications ctc htm ctc","volume":"14","author":"CTCAE","year":"2013"},{"key":"ref201","first-page":"117","article-title":"Zoledronic acid use in cancer patients : more than just supportive care","volume":"21","author":"Coleman","year":"2011","journal-title":"Cancer"},{"key":"ref111","first-page":"003188","article-title":"Bisphosphonates in multiple myeloma a network meta - analysis CD","volume":"12","author":"Mhaskar","year":"2012","journal-title":"Database Syst Rev"},{"key":"ref171","first-page":"15","article-title":"Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer : a systematic metaanalysis","volume":"18","author":"Serpa Neto","year":"2012","journal-title":"review Prostate Cancer Dis"},{"key":"ref11","first-page":"23","article-title":"Malignant spinal compression","volume":"42","author":"Rajer","year":"2008","journal-title":"cord Radiol Oncol"},{"key":"ref261","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/94.19.1458","article-title":"randomized placebo - controlled trial of zoledronic acid in patients with hormone - refractory metastatic prostate carcinoma","author":"Saad","year":"2002","journal-title":"Natl Cancer Inst"},{"key":"ref181","article-title":"Openlabel trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone - sensitive prostate cancer and bone metastases","volume":"19","author":"Polascik","year":"2005","journal-title":"Urology"},{"key":"ref381","first-page":"15","article-title":"Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer : a systematic metaanalysis","volume":"18","author":"Serpa Neto","year":"2012","journal-title":"review Prostate Cancer Dis"},{"key":"ref41","first-page":"163","article-title":"Progressive osteoporosis during androgen deprivation therapy for prostate cancer","author":"Daniell","year":"2000"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long - term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone - refractory prostate cancer","author":"Saad","year":"2004","journal-title":"Cancer Inst"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/ctrv.2000.0210","article-title":"RE bone disease clinical features pathophysiology treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/ctrv.2000.0210","article-title":"RE bone disease clinical features pathophysiology treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"}],"container-title":["Radiology and Oncology"],"original-title":[],"link":[{"URL":"https:\/\/content.sciendo.com\/view\/journals\/raon\/47\/3\/article-p289.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/view\/j\/raon.2013.47.issue-3\/raon-2013-0041\/raon-2013-0041.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T22:53:44Z","timestamp":1590792824000},"score":1,"resource":{"primary":{"URL":"https:\/\/content.sciendo.com\/doi\/10.2478\/raon-2013-0041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,1]]},"references-count":36,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.2478\/raon-2013-0041","relation":{},"ISSN":["1581-3207","1318-2099"],"issn-type":[{"value":"1581-3207","type":"electronic"},{"value":"1318-2099","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9,1]]}}}